Jacobson Pharma Corporation Limited (02633) published its monthly return on movements in securities for February 2026. The authorised and registered share capital remained at 5.00 billion ordinary shares, each with a par value of HKD 0.01, totaling HKD 50.00 million. The issued share capital stayed at 2.00 billion shares, indicating no changes in share issuance or repurchase activities for the month.

The public float requirement remained in compliance under the Main Board Listing Rules. The company reported no new share options exercised over the period, and up to 138.00 million shares may still be issued under its existing share option scheme. No warrants, convertibles, or other share issuance agreements were disclosed, and there were no treasury shares as of the end of February 2026.